Pfizer Signs Academic Collaboration Pact With Peking University To Support Translational R&D Center In Shenzhen
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - After unveiling a plan to build a research and development center in Wuhan last week, Pfizer announced it inked an agreement with Peking University Dec. 1 to fund the university's research projects and to build a translational research and drug discovery center in PKU's Graduate School in Shenzhen, a Chinese city that borders the former British enclave of Hong Kong
You may also be interested in...
Today Asia, Tomorrow The World? AstraZeneca Looks To Align R&D Strategy Across Emerging Markets
WASHINGTON - AstraZeneca PLC is looking to leverage its experience in Asia to catch up with competitors in other fast growing emerging markets like Russia and Brazil, according to Steve Yang, the company's head of R&D in Asia and emerging markets. Yang, who joined AZ in January, is based in Shanghai and reports to R&D President Martin Mackay
Today Asia, Tomorrow The World? AstraZeneca Looks To Align R&D Strategy Across Emerging Markets
WASHINGTON - AstraZeneca PLC is looking to leverage its experience in Asia to catch up with competitors in other fast growing emerging markets like Russia and Brazil, according to Steve Yang, the company's head of R&D in Asia and emerging markets. Yang, who joined AZ in January, is based in Shanghai and reports to R&D President Martin Mackay
Early Days For Discovery Collaborations With Academia In China - China Healthcare Investment Conference
BEIJING - Big Pharma and device companies are looking to test different models to harness a new source of novel technology as China's innovative life science sectors become more developed. Returnees, Chinese researchers and entrepreneurs that study or work in the West before establishing or working for companies in China, may have a large impact on how Western firms approach partnering in China